In a significant stride for obesity treatment, the U.S. Food and Drug Administration (FDA) has given its nod to Foundayo, Eli Lilly’s groundbreaking once-daily oral GLP-1 medication. This approval marks a pivotal moment, offering a new, convenient option for weight management and intensifying the competition in the rapidly expanding GLP-1 market, which already features popular injectables like Lilly’s own Zepbound and rivals Ozempic and Wegovy.
Foundayo: A New Frontier in Weight Management
Foundayo, a glucagon-like peptide-1 (GLP-1) mimetic, operates by replicating a natural hormone that plays a crucial role in metabolic regulation. This includes moderating blood sugar levels, slowing gastric emptying, and signaling satiety to the brain, collectively contributing to significant weight loss.
While Novo Nordisk introduced its oral Wegovy pill in December, requiring administration on an empty stomach, Eli Lilly highlights Foundayo’s flexibility. Patients can take Foundayo at any time of day, free from food or water restrictions, a potential advantage for adherence and patient convenience.
Addressing the Injection Barrier
The demand for GLP-1 medications has soared, often outstripping supply and leading to shortages. Pharmaceutical companies are keenly aware that an oral alternative could dramatically broaden market access and appeal. Beyond manufacturing efficiencies, which promise more consistent supply, the psychological barrier of injections remains a key factor for many potential users.
Ken Custer, executive vice president of Eli Lilly, emphasizes this point: “Beyond supply and affordability, one of the bigger barriers to adoption has been that some patients just don’t want to take an injection. That could be because it’s a needle, but it also may just be that for them, an injection signifies that their condition is more severe than they feel it is at that point. For patients looking to get started with their weight management journey, maybe a pill is an easier place for them to start.” This sentiment underscores the potential for Foundayo to onboard a new segment of patients hesitant about injectables.
Clinical Efficacy and Patient Outcomes
Similar to its injectable counterparts, Foundayo treatment begins with a low dose, gradually increasing to mitigate common gastrointestinal side effects such as nausea, vomiting, and diarrhea.
In an 18-month clinical trial, participants on the highest dose of Foundayo achieved an average weight loss of 27 pounds, or 12.4% of their body weight. This contrasts sharply with the placebo group, which saw a modest average loss of just 2 pounds (less than 1%). While Lilly’s injectable tirzepatide (found in Mounjaro and Zepbound) has demonstrated even greater efficacy with over 20% weight reduction, and Novo Nordisk’s Wegovy pill showed 13.6% weight loss over 16 months, direct head-to-head comparisons between Foundayo and the Wegovy pill are yet to be conducted.
Intriguingly, a study exploring transitions from injectable GLP-1s to Foundayo revealed promising results for weight maintenance. Patients switching from injectable Wegovy to Foundayo regained an average of just 2 pounds, while those transitioning from Zepbound saw an average gain of 11 pounds. This suggests Foundayo could serve as a viable maintenance option for some.
Beyond Weight Loss: Orforglipron’s Broader Potential
The active ingredient in Foundayo, orforglipron, is not solely focused on weight management. It is currently under investigation for its potential in treating a range of other conditions, including type 2 diabetes, obstructive sleep apnea, and osteoarthritis knee pain, hinting at a wider therapeutic impact in the future.
Availability and Expedited Approval
Foundayo is set to become available through Eli Lilly’s direct-to-consumer platform, LillyDirect, with shipping commencing April 6th. Broader availability across U.S. retail pharmacies and telehealth providers is expected soon after. The medication was also part of a November 2025 agreement to be offered via the TrumpRx platform.
Notably, the FDA’s approval process for Foundayo was remarkably swift, taking only 50 days. This expedited review was facilitated by a new pilot program designed to fast-track drugs aligned with national health priorities, a stark contrast to the typical six to ten months for new drug approvals.
For more details, visit our website.
Source: Link
Leave a comment